Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
7 Hills Pharma, LLC
Novartis
GlaxoSmithKline
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
San Raffaele University
Fudan University
St. Jude Children's Research Hospital
GlaxoSmithKline